Rejuvenate Biomed has completed recruitment in its randomized, double-blind, placebo-controlled Phase 2 MINT-COPD trial evaluating RJx-01 in older adults with COPD-induced muscle weakness and sarcopenia.
The trial will assess safety and tolerability alongside measures of muscle strength, physical function and muscle fatigue resistance, and topline data are expected by year-end 2026, the company says.
RJx-01 is described as a first-in-class, multi-pathway therapeutic designed to target mitochondrial dysfunction, inflammation, fibrosis and neuromuscular impairment; the company claims prior Phase 1b data showed meaningful improvements in muscle strength, function and fatigue resistance with an acceptable safety profile.
The study is run in partnership with the University of Leicester and the NIHR Leicester Biomedical Research Centre, led by clinicians at Leicester, and is supported by multimillion-dollar funding from Wellcome Leap’s Dynamic Resilience program, co-funded by Temasek Trust.
The company frames COPD-induced sarcopenia as an unmet medical need with no approved pharmacologic treatments and notes the global burden of the condition.
